108TH CONGRESS 1ST SESSION H.R. 1709

To restore standards to protect the privacy of individually identifiable health information that were weakened by the August 2002 modifications, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

April 10, 2003

Mr. MARKEY (for himself, Mr. ROHRABACHER, Mr. WAXMAN, and Mr. DIN-GELL) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and the Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

- To restore standards to protect the privacy of individually identifiable health information that were weakened by the August 2002 modifications, and for other purposes.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

- 4 This Act may be cited as the "Stop Taking Our
- 5 Health Privacy (STOHP) Act of 2003".

6 SEC. 2. FINDINGS.

7 The Congress finds as follows:

(1) People in the United States are deeply con-1 2 cerned about the confidentiality of their health infor-3 mation. According to a survey conducted by the 4 Princeton Survey Research Associates, 1 in 6 people 5 in the United States has done something out of the 6 ordinary to keep personal health information con-7 fidential, including withholding information, pro-8 viding inaccurate information, or, in some cases, 9 avoiding care entirely.

10 (2) Pursuant to the Health Insurance Port-11 ability and Accountability Act of 1996, commonly re-12 ferred to as "HIPAA" (Public Law 104–191; 110 13 Stat. 1936 et seq.), the Department of Health and 14 Human Services issued comprehensive medical pri-15 vacy regulations, which were promulgated in final 16 form in December 2000.

17 (3) These regulations established a sound foun-18 dation of privacy protections by prohibiting the use 19 or disclosure of an individual's health information 20 unless specifically authorized by the regulations or 21 by the individual. The regulations also required 22 health care providers such as physicians and health 23 clinics, health plans, and health care clearinghouses, 24 which are responsible for handling transactions such 25 as billing between health plans and providers, to notify individuals about privacy practices regarding
disclosure of health information. The regulations
also provided individuals with the right to access and
copy their own health records, and the right to request corrections of their health records, among
other provisions.

7 (4) The regulations took effect on April 14,
8 2000, and required health care providers, health
9 plans (other than small health plans), and health
10 care clearinghouses to comply not later than April
11 14, 2003.

(5) On August 14, 2002, the Department of
Health and Human Services issued modifications to
the December 2000 medical privacy rule that significantly weakened privacy protections.

16 (6) These modifications eliminated the require-17 ment that health care providers, health plans, and 18 health care clearinghouses obtain patient consent be-19 fore using or disclosing patient health information 20 for treatment, payment, or health care operations. 21 This change means that patients' medical informa-22 tion can be used or disclosed without their permis-23 sion for a wide range of purposes, including business 24 activities that have nothing to do with patient care, 25 such as the sale or merger of a health maintenance

1 organization (HMO). This change also permits the use and disclosure of information in existing medical 2 3 records even though patients disclosed the informa-4 tion with the understanding and expectation that it 5 would not be used or disclosed without their consent. 6 The elimination of consent compromises the con-7 fidentiality that is the heart of physician-patient re-8 lationships and is indispensable for the delivery of 9 high-quality health care.

10 (7) The August 2002 modifications also under-11 mined medical privacy protections by expanding the 12 circumstances under which patients' information can 13 be shared without their knowledge or consent to in-14 clude activities that consumers typically consider 15 marketing. This change permits pharmacies and 16 other providers to use consumers' medical informa-17 tion without their permission to mail them unsolic-18 ited drug product recommendations. Furthermore, 19 providers are not required to disclose fees paid to 20 them by drug companies for sending such commu-21 nications nor provide consumers with the choice to 22 opt out of such future communications.

(8) The August 2002 modifications further undermined medical privacy protections by changing
the section of the rule governing public health. The

1 change allows providers to disclose medical informa-2 tion without patient permission to entities regulated 3 by the Food and Drug Administration, such as phar-4 maceutical companies and medical device manufac-5 turers, for a broad range of purposes including mar-6 keting campaigns. In contrast, the December 2000 7 rule allowed nonconsensual disclosure of patient 8 health information for a limited list of public health-9 related activities, such as reporting serious side ef-10 fects from a prescription drug to the Food and Drug 11 Administration.

(9) Reversal of the August 2002 modifications
to the medical privacy rule is integral to any effort
to ensure privacy protections for consumers' personal health information and preserve access to
high-quality health care in the United States.

17 (10) Congress should restore core medical pri18 vacy protections of the December 2000 medical pri19 vacy rule by—

20 (A) reinstating the patient consent require21 ment for treatment, payment, and health care
22 operations, while ensuring that the requirement
23 does not impede important health care activities
24 such as filling pharmaceutical prescriptions and
25 making physician referrals;

 $\mathbf{5}$

1	(B) returning to the December 2000 defi-
2	nition of "marketing" and thus ensuring that
3	activities typically considered "marketing," such
4	as drug companies paying pharmacies to send
5	product recommendations to patients, fall under
6	the rule's privacy protections governing mar-
7	keting activities; and
8	(C) eliminating the broad "public health"
9	loophole created by the August 2002 rule.
10	SEC. 3. PURPOSE.
11	The purpose of this Act is to restore patient privacy
12	protections essential for high-quality health care that were
13	undermined by the August 2002 modifications of the De-
14	cember 2000 medical privacy rule.
15	SEC. 4. RESTORATION OF PRIVACY PROTECTIONS.
16	(a) Consent for Uses or Disclosures to Carry
17	OUT TREATMENT, PAYMENT, OR HEALTH CARE OPER-
18	ATIONS.—
19	(1) IN GENERAL.—The modifications made to
20	section 164.506 of title 45, Code of Federal Regula-
21	tions, by the August 2002 medical privacy rule shall
22	have no force or effect.
23	(2) CLARIFICATION REGARDING INSTANCES
24	WHEN CONSENT IS NOT REQUIRED.— In addition to
25	the circumstances described in the December 2000

1	medical privacy rule, and notwithstanding any provi-
2	sion to the contrary, such section 164.506 shall be
3	construed and applied so as to permit a health care
4	provider to use or disclose an individual's protected
5	health information without obtaining the prior con-
6	sent of the individual in the following circumstances:
7	(A) A health care provider may use or dis-
8	close an individual's protected health informa-
9	tion to fill or dispense a prescription, search for
10	drug interactions related to that prescription,
11	and determine eligibility and obtain authoriza-
12	tion for payment regarding that prescription, if
13	the health care provider obtains written consent
14	from the individual as soon as practicable.
15	(B) A health care provider may use or dis-
16	close an individual's protected health informa-
17	tion to carry out treatment of that individual
18	if—
19	(i) the individual and the health care
20	provider have not had in-person commu-
21	nication regarding such treatment;
22	(ii) obtaining consent would be im-
23	practicable;
24	(iii) the health care provider deter-
25	mines, in the exercise of professional judg-

1	ment, that the individual's consent is clear-
2	ly inferred from the circumstances, such as
3	an order or referral from another health
4	care provider; and
5	(iv) the health care provider obtains
6	written consent from the individual as soon
7	as practicable.
8	(b) Marketing.—
9	(1) IN GENERAL.—The modifications made by
10	the August 2002 medical privacy rule to the defini-
11	tion of the term "marketing" in section 164.501 of
12	title 45, Code of Federal Regulations, shall have no
13	force or effect.
14	(2) TREATMENT OF CERTAIN COMMUNICA-
15	TIONS.—The exception for oral communications in
16	paragraph (2)(i) of the definition of the term "mar-
17	keting" in section 164.501 of title 45, Code of Fed-
18	eral Regulations, as contained in the December 2000
19	medical privacy rule, shall have no force or effect.
20	(3) Authorizations for marketing.—Sec-
21	tion 164.508 of title 45, Code of Federal Regula-
22	tions, shall be construed and applied so as to require
23	that, if an authorization is required for a use or dis-
24	closure for marketing, the authorization shall be
25	considered invalid unless it—

1	(A) uses the term "marketing";
2	(B) states that the purpose of the use or
3	disclosure involved is marketing;
4	(C) describes the specific marketing uses
5	and disclosures authorized, including whether
6	the protected health information involved—
7	(i) may be used for purposes internal
8	to the covered entity;
9	(ii) may be disclosed to, and used by,
10	a business associate of the covered entity;
11	and
12	(iii) may be disclosed to, and used by,
13	any person or entity other than a business
14	associate of the covered entity; and
15	(D) states that the use or disclosure of
16	protected health information for marketing will
17	directly result in remuneration to the covered
18	entity from a third party, in any case in which
19	a covered entity expects, or reasonably should
20	expect, that such remuneration will occur.
21	(c) PUBLIC HEALTH.—The modifications made to
22	section 164.512(b)(1)(iii) of title 45, Code of Federal Reg-
23	ulations, by the August 2002 medical privacy rule shall
24	have no force or effect.

10

1 SEC. 5. DEFINITIONS; EFFECTIVE DATE.

2 (a) IN GENERAL.—For purposes of this Act:

3 (1) DECEMBER 2000 MEDICAL PRIVACY RULE. 4 The term "December 2000 medical privacy rule" 5 means the final rule on standards for privacy of in-6 dividually identifiable health information published 7 on December 28, 2000, in the Federal Register (65 8 Fed. Reg. 82462), including the provisions of title 9 45, Code of Federal Regulations, revised or added 10 by such rule.

(2) AUGUST 2002 MEDICAL PRIVACY RULE.—
The term "August 2002 medical privacy rule"
means the final rule, published on August 14, 2002,
in the Federal Register (67 Fed. Reg. 53182), that
modified the December 2000 medical privacy rule.

16 (b) OTHER TERMS DEFINED.—For purposes of this17 Act:

(1) BUSINESS ASSOCIATE; COVERED ENTITY;
HEALTH CARE PROVIDER.—The terms "business associate", "covered entity", and "health care provider" shall have the meaning given such terms in
section 160.103 of title 45, Code of Federal Regulations, as contained in the December 2000 medical
privacy rule.

25 (2) DISCLOSURE; INDIVIDUAL, PROTECTED
26 HEALTH INFORMATION; TREATMENT; USE.—The
•HR 1709 IH

terms "disclosure", "individual", "protected health
 information", "treatment", and "use" shall have the
 meaning given such terms in section 164.501 of title
 45, Code of Federal Regulations, as contained in the
 December 2000 medical privacy rule.

6 (c) EFFECTIVE DATE; NO REGULATIONS RE7 QUIRED.—This Act shall take effect on the date of the
8 enactment of this Act and does not require the issuance
9 of regulations.

 \bigcirc